X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DR. REDDYS LAB - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DR. REDDYS LAB SANOFI INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 30.0 27.9 107.5% View Chart
P/BV x 5.3 2.9 184.3% View Chart
Dividend Yield % 1.7 1.0 172.8%  

Financials

 SANOFI INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DR. REDDYS LAB
Mar-16
SANOFI INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs4,5604,383 104.0%   
Low Rs4,4002,750 160.0%   
Sales per share (Unadj.) Rs1,028.5920.1 111.8%  
Earnings per share (Unadj.) Rs129.0126.1 102.3%  
Cash flow per share (Unadj.) Rs186.0183.0 101.6%  
Dividends per share (Unadj.) Rs68.0020.00 340.0%  
Dividend yield (eoy) %1.50.6 270.7%  
Book value per share (Unadj.) Rs753.6685.8 109.9%  
Shares outstanding (eoy) m23.03170.61 13.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.43.9 112.4%   
Avg P/E ratio x34.728.3 122.8%  
P/CF ratio (eoy) x24.119.5 123.6%  
Price / Book Value ratio x5.95.2 114.3%  
Dividend payout %52.715.9 332.5%   
Avg Mkt Cap Rs m103,174608,481 17.0%   
No. of employees `0003.621.7 16.7%   
Total wages/salary Rs m3,59231,874 11.3%   
Avg. sales/employee Rs Th6,537.77,244.4 90.2%   
Avg. wages/employee Rs Th991.41,470.9 67.4%   
Avg. net profit/employee Rs Th819.8992.8 82.6%   
INCOME DATA
Net Sales Rs m23,686156,978 15.1%  
Other income Rs m7082,693 26.3%   
Total revenues Rs m24,394159,671 15.3%   
Gross profit Rs m5,28134,587 15.3%  
Depreciation Rs m1,3139,705 13.5%   
Interest Rs m15824 1.8%   
Profit before tax Rs m4,66126,751 17.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6915,237 32.3%   
Profit after tax Rs m2,97021,514 13.8%  
Gross profit margin %22.322.0 101.2%  
Effective tax rate %36.319.6 185.3%   
Net profit margin %12.513.7 91.5%  
BALANCE SHEET DATA
Current assets Rs m15,673118,201 13.3%   
Current liabilities Rs m6,67868,368 9.8%   
Net working cap to sales %38.031.7 119.6%  
Current ratio x2.31.7 135.7%  
Inventory Days Days7660 126.7%  
Debtors Days Days2297 23.0%  
Net fixed assets Rs m8,09872,265 11.2%   
Share capital Rs m230853 27.0%   
"Free" reserves Rs m17,088111,548 15.3%   
Net worth Rs m17,356117,009 14.8%   
Long term debt Rs m010,690 0.0%   
Total assets Rs m25,400200,104 12.7%  
Interest coverage x311.733.5 931.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.8 118.9%   
Return on assets %11.811.2 105.3%  
Return on equity %17.118.4 93.1%  
Return on capital %26.921.6 124.8%  
Exports to sales %24.546.3 52.9%   
Imports to sales %28.09.0 312.6%   
Exports (fob) Rs m5,80172,618 8.0%   
Imports (cif) Rs m6,62714,050 47.2%   
Fx inflow Rs m7,14575,405 9.5%   
Fx outflow Rs m6,84627,115 25.2%   
Net fx Rs m29948,290 0.6%   
CASH FLOW
From Operations Rs m3,22640,476 8.0%  
From Investments Rs m-1,555-19,421 8.0%  
From Financial Activity Rs m-1,818-17,009 10.7%  
Net Cashflow Rs m-1474,046 -3.6%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.4 266.7%  
FIIs % 14.6 35.3 41.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   15,184 75,885 20.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON LTD  J.B.CHEMICALS  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 23, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - SUN PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS